Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats.
We investigated the protective effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against two kinds of experimental disseminated intravascular coagulation (DIC) in rats. Endotoxin-induced experimental DIC was induced by a 4-h sustained infusion of endotoxin at a dose of 100 mg/kg. Thromboplastin-induced experimental DIC was induced by a bolus injection of thromboplastin at a dose of 150 mg/kg. The rats were orally administered DX-9065a at 10, 30 or 100 mg/kg 30 min before endotoxin or thromboplastin injection. In both DIC models, DX-9065a showed a protective effect against DIC, at all doses and in all parameters, including fibrin/fibrinogen degradation products (FDP), fibrinogen level, prothrombin time, activated partial thromboplastin time, platelet count and the number of renal glomeruli with fibrin thrombi. When DX-9065a was orally administrated at 100 mg/kg without endotoxin or thromboplastin, no significant changes were seen in hemostatic parameters except PT and APTT, and no fibrin thrombi or abnormal bleeding were seen in renal specimens. These findings suggest that the new oral anti-Xa drug, DX-9065a, has an effect in reducing the severity of DIC. However, further dose-finding and safety studies of this drug have still to be assessed.
Yamazaki
M
M
Department of Internal Medicine (III), Kanazawa University School of Medicine, Japan.
Asakura
H
H
Aoshima
K
K
Saito
M
M
Jokaji
H
H
Uotani
C
C
Kumabashiri
I
I
Morishita
E
E
Ikeda
T
T
Matsuda
T
T
D000284:Administration, Oral; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D004353:Drug Evaluation, Preclinical; D004731:Endotoxins / Q000633:toxicity; D065427:Factor Xa Inhibitors; D005337:Fibrin / Q000032:analysis; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D007678:Kidney Glomerulus / Q000473:pathology; D008297:Male; D009281:Naphthalenes / Q000008:administration & dosage / Q000627:therapeutic use*; D010314:Partial Thromboplastin Time; D010976:Platelet Count; D011422:Propionates / Q000008:administration & dosage / Q000627:therapeutic use*; D011517:Prothrombin Time; D051381:Rats; D017208:Rats, Wistar; D013925:Thromboplastin / Q000633:toxicity
C086910:(2S)-2-(4-(((3S)-1-acetimidoyl-3-pyrrolidinyl)oxy)phenyl)-3-(7-amidino-2-naphtyl)propanoic acid; D000925:Anticoagulants; D004731:Endotoxins; D065427:Factor Xa Inhibitors; D005338:Fibrin Fibrinogen Degradation Products; D009281:Naphthalenes; D011422:Propionates; D005337:Fibrin; D005340:Fibrinogen; D013925:Thromboplastin